ライフサイエンスコーパス: MRSA infection

1 riaxone/Cefotaxime against highly pathogenic MRSA infection.

2 ew and effective antimicrobial agent against MRSA infection.

3 he protective host defense against recurring MRSA infection.

4 anism of host resistance against intradermal MRSA infection.

5 ospital with S. aureus HCAP have evidence of MRSA infection.

6 ally sterile sites in patients with invasive MRSA infection.

7 now an abundant cause of community-acquired MRSA infection.

8 patients had a documented risk factor for CA-MRSA infection.

9 ercent of patients were hospitalized for the MRSA infection.

10 or health problems were not associated with MRSA infection.

11 fold increase in the incidence of subsequent MRSA infection.

12 thletes and estimate the risk for subsequent MRSA infection.

13 directly contributes to pathogenicity during MRSA infection.

14 for the antibiotic selected for treatment of MRSA infection.

15 ive MSSA infection and infants with invasive MRSA infection.

16 novel approaches to address the challenge of MRSA infection.

17 a suitable target for preventing or treating MRSA infection.

18 ancomycin for the treatment of intracellular MRSA infection.

19 atients is associated with increased risk of MRSA infection.

20 ion contributed to lower rates of nosocomial MRSA infection.

21 coccus aureus (MRSA) have increased risk for MRSA infection.

22 %, and only 1 of 5 deaths was related to the MRSA infection.

23 anscriptional regulators in the pathology of MRSA infection.

24 nce and leads to susceptibility to secondary MRSA infection.

25 n SEB-neutralizing mAb, is effective against MRSA infection.

26 eutic strategies to address the challenge of MRSA infection.

27 nt and positive immunomodulatory role during MRSA infections.

28 of the MRSA bundle on health care-associated MRSA infections.

29 future prophylaxis or new treatments for CA-MRSA infections.

30 expressed during superficial and invasive CA-MRSA infections.

31 m children with active known or suspected CA-MRSA infections.

32 screening or reporting in efforts to reduce MRSA infections.

33 ed in 2001, accounted for 82.1% (412/502) of MRSA infections.

34 iant of PVL that is strongly associated with MRSA infections.

35 tics may represent a novel approach to treat MRSA infections.

36 Six strain types accounted for 88.2% of all MRSA infections.

37 miology of America for control of nosocomial MRSA infections.

38 and have previously been associated with CA-MRSA infections.

39 administered to 206 trainees, 22 of whom had MRSA infections.

40 among isolates from patients with recurrent MRSA infections.

41 re now available for the treatment of severe MRSA infections.

42 ass of antibiotics holds promise in fighting MRSA infections.

43 ices that are effective at limiting invasive MRSA infections.

44 timal bacterial clearance during respiratory MRSA infections.

45 unct antivirulence therapy for patients with MRSA infections.

46 ime trends, and long-term risk of subsequent MRSA infections.

47 MRSA) infections were discriminated from non-MRSA infections.

48 of best practice for treating patients with MRSA infections.

49 methicillin-resistant Staphylococcus aureus (MRSA) infection.

50 methicillin-resistant Staphylococcus aureus (MRSA) infection.

51 mice after methicillin-resistant S. aureus (MRSA) infection.

52 o eliminate methicillin-resistant S. aureus (MRSA) infection.

53 methicillin-resistant Staphylococcus aureus (MRSA) infections.

54 eatment for methicillin-resistant S. aureus (MRSA) infections.

55 hicillin-resistant Staphylococcus aureus (CA-MRSA) infections.

56 e methicillin-resistantStaphylococcus aureus(MRSA) infections.

57 methicillin-resistant Staphylococcus aureus (MRSA) infections.

58 3 (17%) had methicillin-resistant S. aureus (MRSA) infections.

59 methicillin-resistant Staphylococcus aureus (MRSA) infections.

60 a significant reduction in Gram-positive or MRSA infections?

61 Among the 283 MRSA infections, 127 (44.9%) were defined as community-a

62 Of 1100 MRSA infections, 131 (12%) were community-associated and

63 There were 19 cases of MRSA infection (16.5%).

64 2008, there were 21,503 episodes of invasive MRSA infection; 17,508 were health care associated.

65 ay was significantly longer for persons with MRSA infection (33 days vs. 22 days; p=.047).

66 zation than those with clindamycin-resistant MRSA infections (71%; P = 0.042).

67 meticillin-resistant Staphylococcus aureus (MRSA) infections across a region of Scotland.

68 Invasive MRSA infection affects certain populations disproportion

69 egies, we assessed risk factors for invasive MRSA infection after acute-care hospitalizations.

70 pidemiology of and recent trends in invasive MRSA infections among dialysis patients.

71 However, the decreases in invasive MRSA infections among recently discharged patients have

72 methicillin-resistant Staphylococcus aureus (MRSA) infections among hospitalized patients.

73 Fourteen percent of patients with CA-MRSA infections and 3% of patients with CA-MSSA infectio

74 drawn from an epidemiological network of CA-MRSA infections and colonizations in northern Manhattan

75 dence rates and estimated number of invasive MRSA infections and in-hospital deaths among patients wi

76 A major issue is to identify the sources of MRSA infections and to monitor their epidemic spread.

77 methicillin-resistant Staphylococcus aureus (MRSA) infections and widespread use of vancomycin, MRSA

78 Compared to methicillin-sensitive S. aureus, MRSA infections are associated with greater morbidity an

79 Additionally, CA-MRSA infections are epidemic in some countries.

80 es of antibiotics, and treatment options for MRSA infections are limited.

81 Community-associated MRSA infections are now a common and serious problem.

82 methicillin-resistant Staphylococcus aureus (MRSA) infections are a burden on the health care system.

83 Methicillin-resistant Staphylococcus aureus (MRSA) infections are a global public health problem.

84 hicillin-resistant Staphylococcus aureus (CA-MRSA) infections are encroaching upon nosocomial setting

85 hicillin-resistant Staphylococcus aureus (CA-MRSA) infections are frequently associated with strains

86 methicillin-resistant Staphylococcus aureus (MRSA) infections are increasing and may now involve pers

87 hicillin-resistant Staphylococcus aureus (CA-MRSA) infections are predominantly those affecting skin

88 methicillin-resistant Staphylococcus aureus (MRSA) infections are reported as decreasing, but recent

89 Health-care-associated MRSA infections arise in individuals with predisposing r

90 contrast, many community-associated MRSA (CA-MRSA) infections arise in otherwise healthy individuals

91 rsal surveillance, the prevalence density of MRSA infection at each body site had a statistically sig

92 d the seasonality of community acquired (CA)-MRSA infections at the population level.

93 hereas the annual ratio of CA-MRSA in ocular MRSA infections averaged 66.1% and tended to increase ov

94 methicillin-resistant Staphylococcus aureus (MRSA) infections between 2010 and 2014 primarily reflect

95 Injecting drug users accounted for 49% of CA-MRSA infections but only 19% of the HA-MRSA infections (

96 hicillin-resistant Staphylococcus aureus (CA-MRSA) infections, but there are limited data regarding t

97 methicillin-resistant Staphylococcus aureus (MRSA) infections by demonstrating that oxacillin can be

98 children in the Midwest suggest that serious MRSA infections can be acquired in the community in rura

99 atients with traditional hospital-associated MRSA infections, compared with patients with CA-MRSA inf

100 The restricted treatment options for CA-MRSA infections compound the effect of enhanced virulenc

101 methicillin-resistant Staphylococcus aureus (MRSA) infection continues to rise in many health care se

102 l, particularly if successful hospital-based MRSA infection control programmes are maintained.

103 as, rates of invasive health care-associated MRSA infections decreased among patients with health car

104 Incidence of invasive MRSA infections decreased from 6.5 to 4.2 per 100 dialys

105 st injection-drug use (43 percent); previous MRSA infection, diabetes, and chronic hepatitis C (21 pe

106 ty-acquired methicillin-resistant S. aureus (MRSA) infections, displays the giant protein Ebh on its

107 Six of seven institutions had at least one MRSA infection during the study.

108 1598 in-hospital deaths among patients with MRSA infection during the surveillance period.

109 ubjects were followed for the development of MRSA infection during their ICU stay.

110 of MRSA nasal colonization for ICU-acquired MRSA infections, either lower respiratory tract infectio

111 ese cases underscore the changing profile of MRSA infections, especially in the community-based setti

112 was no difference in clinical resolution of MRSA infection even if the infecting organism was resist

113 cantly increases the severity of bloodstream MRSA infection, even when administered in conjunction wi

114 tic 75b) was efficacious in a mouse model of MRSA infection, exhibiting a long half-life, a high volu

115 invasive (from a normally sterile body site) MRSA infections from 2005 through 2008 were evaluated an

116 Patients with MRSA infection had a six-fold higher mortality rate and

117 Optimal outpatient therapy for MRSA infections has yet to be determined, but this matte

118 Although methicillin-resistant S. aureus (MRSA) infection has become increasingly reported, popula

119 hicillin-resistant Staphylococcus aureus (CA-MRSA) infection has been defined as an MRSA infection in

120 Methicillin-resistant Staphylococcus aureus (MRSA) infection has emerged in patients who do not have

121 hicillin-resistant Staphylococcus aureus (CA-MRSA) infections has become a significant health care ch

122 methicillin-resistant Staphylococcus aureus (MRSA) infections has been occurring for the last 15 year

123 Methicillin-resistant Staphylococcus aureus (MRSA) infections have become common among both hospitali

124 methicillin-resistant Staphylococcus aureus (MRSA) infections have been acquired primarily in nosocom

125 hicillin-resistant Staphylococcus aureus (CA-MRSA) infections have spawned efforts to define unique v

126 the "gold standard" of treatment for serious MRSA infections; however, the emergence of less-suscepti

127 roles in immunity to cutaneous and invasive MRSA infection in a mouse model of SSSI.

128 s (CA-MRSA) infection has been defined as an MRSA infection in a patient who lacks specific risk fact

129 combinant Reg3gamma administration 4 h after MRSA infection in alcohol-intoxicated mice rescued USA30

130 decolonization without screening to prevent MRSA infection in intensive-care unit (ICU) patients.

131 Four recent deaths due to MRSA infection in previously healthy children in the Mid

132 398, may be involved in livestock-associated MRSA infection in the United States.

133 ges and neutrophils, and protected mice from MRSA infection in two model systems.

134 Seasonal variation of MRSA infections in hospital settings has been widely obs

135 iven the high rates of primary and recurring MRSA infections in humans, it appears that antibodies to

136 The rates of health care-associated MRSA infections in ICUs had not changed in the 2 years b

137 nterior nares was a significant predictor of MRSA infections in liver transplant recipients.

138 period, the rates of health care-associated MRSA infections in non-ICUs fell from 0.47 per 1000 pati

139 We evaluated MRSA infections in patients identified from population-b

140 Community-acquired MRSA infections in the absence of identified risk factor

141 sociated MRSA (CA-MRSA) has caused increased MRSA infections in the general population, including chi

142 aureus (MRSA) USA300 is the leading cause of MRSA infections in the United States and has caused an e

143 ities and to estimate the burden of invasive MRSA infections in the United States in 2005.

144 the current community-associated epidemic of MRSA infections in the United States.

145 te information on the scope and magnitude of MRSA infections in the US population is needed.

146 The rate of subsequent MRSA infections in USA300-positive versus -negative pati

147 ections and methicillin-resistant S. aureus (MRSA) infections in 4 Connecticut metropolitan areas (po

148 methicillin-resistant Staphylococcus aureus (MRSA) infections in children have occurred primarily in

149 hicillin-resistant Staphylococcus aureus (CA-MRSA) infections in patients without traditional risk fa

150 methicillin-resistant Staphylococcus aureus (MRSA) infections in the outpatient setting has led to a

151 methicillin-resistant Staphylococcus aureus (MRSA) infections in the United States have been caused b

152 has been a substantial decrease in invasive MRSA infection incidence among dialysis patients.

153 Whether there have been changes in MRSA infection incidence as these programs become establ

154 independently associated with postdischarge MRSA infection included MRSA colonization (matched odds

155 e being developed primarily for treatment of MRSA infections, including tedizolid, dalbavancin, and o

156 hicillin-resistant Staphylococcus aureus (CA-MRSA) infections, including serious invasive infections

157 The association with CO-PVL-negative MRSA infection increased across quartiles of dairy/veal

158 Notably, the risk of developing MRSA infections increased among colonized hemodialysis p

159 significantly associated with mortality for MRSA infection irrespective of the source of infection o

160 In areas in which community-associated MRSA infection is endemic, empirical treatment of suspec

161 dominant bacteria species was S. aureus and MRSA infection is increasingly prevalent.

162 Methicillin-resistant Staphylococcus aureus (MRSA) infection is a global health care problem.

163 Methicillin-resistant Staphylococcus aureus (MRSA) infection is a serious threat to the public health

164 hicillin-resistant Staphylococcus aureus (CA-MRSA) infections is increasing in the United States, and

165 A infections, compared with patients with CA-MRSA infections, is independent of the vancomycin MIC, s

166 The 12 epidemiologically defined CA-MRSA infection isolates were either ST1 (n = 4) or ST8 (

167 Among the CA-MRSA infection isolates, 8 (67%) were PVL(+).

168 culminate in lysis of neutrophils during CA-MRSA infection may serve as a novel therapeutic interven

169 o have sex with men, and multidrug-resistant MRSA infection might be sexually transmitted in this pop

170 In MRSA infection mouse model, MCL down-regulated the expre

171 ospital discharge than infants with invasive MRSA infections (n = 110).

172 During the 2003 football season, eight MRSA infections occurred among 5 of the 58 Rams players

173 Traditionally, MRSA infections occurred exclusively in hospitals and we

174 Gram-positive related infections and MRSA infections occurred in 1(1.18%)/0(0%) of Vancomycin

175 Invasive MRSA infections occurred more often at a younger postnat

176 methicillin-resistant Staphylococcus aureus (MRSA) infections occurred in US dialysis patients in 201

177 methicillin-resistant Staphylococcus aureus (MRSA) infection occurs at highly endemic levels in inten

178 of CA-MRSA infections but only 19% of the HA-MRSA infections (odds ratio, 4.2; 95% confidence interva

179 tly associated with MRSA pneumonia: previous MRSA infection or colonisation (odds ratio 6.21, 95% CI

180 Inpatients with a history of MRSA infection or colonization enrolled between December

181 iologic purposes to describe the trend in CA-MRSA infections over time.

182 primary outcomes were prevalence density of MRSA infections per 1000 occupied bed days (OBDs) in hos

183 Methicillin-resistant Staphylococcus aureus (MRSA) infections pose a major challenge in health care,

184 Methicillin-resistant Staphylococcus aureus (MRSA) infections present a serious challenge because of

185 In order to decrease rates of MRSA infection, preventive efforts need to be directed t

186 .7 to 101.6]; P < 0.001) independent of past MRSA infection (relative risk, 2.1 [CI, 1.2 to 3.7]; P =

187 y inflammatory response in the lung after CA-MRSA infection remains largely undefined.

188 le data suggest that the optimal therapy for MRSA infections remains unclear.

189 equency or not significantly associated with MRSA infection risk in our population of newly identifie

190 ischarge was similar after invasive MSSA and MRSA infections (risk ratio, 1.19; 95% CI, 0.96-1.49).

191 [95% CI], 3.56 to 10.72; P < 0.0001), prior MRSA infection (RR, 3.97; 95% CI, 1.94 to 8.12; P = 0.00

192 adoptively transferred to burned mice at the MRSA infection site, an abscess formed, and the infectio

193 ntribution of this leukotoxin to invasive CA-MRSA infections such as pneumonia remains controversial.

194 Using a murine model of intradermal MRSA infection, the therapeutic efficacy of synthetic S.

195 d in jails and prisons, but risk factors for MRSA infection there are not known.

196 lso at highest risk for community-associated MRSA infection; these subgroups included individuals wit

197 inal results linked the dramatic increase in MRSA infections to an expanding community reservoir of M

198 We evaluated patients with invasive MRSA infections to assess differences in outcomes betwee

199 rses of 4 subjects with 3-6 recurrent USA300 MRSA infections, using patient clinical data, including

200 rm (6-20 months) probability of developing a MRSA infection was 19% among colonized hemodialysis pati

201 MRSA infection was associated with increased length of s

202 MRSA infection was significantly associated with the lin

203 he incidence rate of hospital-onset invasive MRSA infections was 1.02 per 10,000 population in 2005 a

204 The 2011 national estimated number of MRSA infections was 15 169.

205 methicillin-resistant Staphylococcus aureus (MRSA) infection was 24% and multidrug resistance (MDR) w

206 om sample of patients with culture-confirmed MRSA infection; we oversampled patients from the Geising

207 pendently associated with community-acquired MRSA infection were black race (prevalence ratio, 1.53 [

208 recent culture-positive community-associated MRSA infection were enrolled from 2012 to 2013 at St Lou

209 7 cases of community-associated [correction] MRSA infection were reported, representing between 8 and

210 CA-MRSA infections were associated with a more adverse impa

211 Forty-six (74%) of the 62 MRSA infections were classified as community acquired.

212 Most MRSA infections were health care-associated: 5250 (58.4%

213 Nearly all MRSA infections were inferred to be USA300.

214 Patients with clindamycin-susceptible MRSA infections were less likely (59%) to have nasal col

215 Risk factors for community-acquired MRSA infections were not significantly different from th

216 Epidemic foci of CA-MRSA infections were reported in jails and prisons, but

217 of infants who died after invasive MSSA and MRSA infections were similar at 237 of 2474 (9.6%) and 1

218 Population-based data for invasive MRSA infections were used to identify 2 cohorts: (1) non

219 methicillin-resistant Staphylococcus aureus (MRSA) infections were discriminated from non-MRSA infect

220 Severe invasive MRSA infections, which include pneumonia, are difficult

221 tibility testing in 100 of 175 patients with MRSA infection who received antibiotics (57 percent).

222 The inability to contain MRSA infection with beta-lactam antibiotics is a continu

223 these outcomes observed with vancomycin for MRSA infections with elevated vancomycin MIC values.

224 methicillin-resistant Staphylococcus aureus (MRSA) infections with minimum inhibitory concentration (

225 methicillin-resistant Staphylococcus aureus (MRSA) infections with vancomycin MICs of 2 mug/ml and co

226 o current clinical practice for treatment of MRSA infection, with the potential to significantly impr

227 cus aureus (MRSA) clones are responsible for MRSA infections worldwide, and those of different lineag